ENTOD Pharmaceuticals (including its subsidiaries and/or associate companies) announced the launch of CYCLOTEARS® eye drops in India and its various global markets for patients with Inflammatory Dry Eye Disease (DED), a commonly occurring condition.

CYCLOTEARS® eye drops would be the first dry eye therapy in the world that incorporates the company’s indigenously developed proprietary self-emulsifying drug delivery system (SEDDS™) technology.

Nikkhil K Masurkar, CEO, Entod Pharmaceuticals said “This novel technology used in CYCLOTEARS® eye drops has been developed by Indian scientists at our Department of Scientific and Industrial Research (DSIR) accredited research centre. We are also associated with leading eye research institutes across India in the development phase. This technology is also backed by strong Indian-generated clinical evidence published in international journals. We are excited about the launch of CYCLOTEARS® eye drops which would provide a newer therapeutic approach to treat inflammatory DED in India”.

The prevalence of DED in India is higher than the global prevalence and stands at almost 32%, of which 90% were affected with moderate/severe DED. Studies have also shown that over-exposure to screens such as television, smartphones, computers, tablets & laptops, or “screen time” significantly correlates with the severity of DED. It is projected that the prevalence of DED is likely to increase to 45% in India’s urban population by 2030.

The previous year Entod Pharmaceuticals announced the development of PresVu, an eyedrop to treat presbyopia which was in the final stage of development. According to the company, these eye drops have the potential to remove the need for reading glasses. Also, in the year 2022, Entod Pharmaceuticals achieved the final Nod from DCGI for the phase 3 trial for low-dose atropine eye drops called Myatro 0.01%. The company has been playing a major role in eye-related treatment in India by manufacturing and bringing eye drops to treat major eye health problems.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.